New CCO to accelerate precision medicine and diagnostics growth


PrecisionLife, a leading innovator in precision medicine for complex chronic diseases, is excited to announce the appointment of Bill Keating as its new Chief Commercial Offi cer (CCO) for Diagnostics and Healthcare. With over two decades of expertise in corporate and business development across the healthcare and diagnostics sectors, Bill will spearhead the commercialisation of PrecisionLife’s pioneering Mechanostic® tests, designed to predict, prevent, and manage chronic diseases on a global scale.


Bill’s career includes senior roles at industry giants such as Philips Healthcare, Zephyr AI, and Foundation Medicine, where he successfully led the adoption of breakthrough diagnostic solutions. His strategic vision and leadership will be crucial in advancing PrecisionLife’s next-generation diagnostic tools, which aim to transform the management of chronic diseases affecting billions of patients worldwide.


“I’m incredibly excited to join PrecisionLife at this critical juncture,” said Bill Keating. “The company’s platform is truly unique, offering scalable insights into complex diseases that have long eluded conventional medicine. PrecisionLife is at the forefront of a new era in healthcare, where predicting and preventing chronic diseases is not just a possibility but a reality. I look


forward to driving the growth and global impact of our precision medicine solutions.”


Steve Gardner, CEO of PrecisionLife, expressed his enthusiasm about Bill’s appointment: “Bill brings invaluable experience in scaling high-impact healthcare companies, making him the ideal leader to guide our commercial strategy. As we expand our reach and collaborate with healthcare systems worldwide, his expertise will be essential in bringing our groundbreaking solutions to market and improving patient outcomes.”


PrecisionLife’s innovative diagnostic tools utilise proprietary insights to offer non-invasive, genotypic testing that pinpoints the genetic causes of complex diseases. The company’s personalised approach supports targeted treatment, optimising patient care while reducing healthcare ineffi ciencies. Bill Keating’s leadership will ensure the rapid adoption of these transformative solutions as they redefi ne chronic disease management.


More information online: ilmt.co/PL/YQXw 64084pr@reply-direct.com


Bill Keating.


New network sets the stage for breakthroughs in advanced therapy regulation


A new initiative aims to revolutionise the regulatory landscape for advanced therapies in the UK, ensuring patients can quickly access transformative treatments. A collaboration between the Cell and Gene Therapy Catapult (CGT Catapult) and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI) seeks to create a dynamic framework that supports the swift development, testing, and rollout of cutting-edge therapies. With funding from Innovate UK and support from the MHRA, this network brings together regulators, researchers, and industry leaders to drive innovation while maintaining patient safety.


Advanced therapies, such as gene and cell treatments, offer unprecedented potential to change the way diseases are treated. However, their complexity demands a regulatory system that adapts to the unique challenges these therapies present. The new network aims to collaborate with UK regulators, particularly the MHRA, to develop effective regulatory strategies tailored to these next-generation treatments. Its focus is on ensuring that the regulatory environment encourages innovation while safeguarding public health.


Through this collaborative effort, the network will create a


regulatory ecosystem that positions the UK as a global leader in advanced therapy development. By identifying key regulatory solutions and sharing them with stakeholders across the healthcare and research sectors, the initiative will work to streamline the path from development to patient access, ensuring timely, safe, and effective treatments.


Matthew Durdy, Chief Executive of CGT Catapult, emphasised the importance of this initiative: “Advanced therapies present both a signifi cant opportunity for patients and a chance for the UK to lead globally in this fi eld. This network will play a key role in making that happen.”


Melanie Calvert, Deputy Director of CRSI, underscored the importance of involving the patient voice in shaping regulatory decisions. “As the number of advanced therapies grows, it’s crucial that regulatory frameworks evolve to meet the needs of patients. Our work will ensure these therapies are developed with patient-centric insights, leading to quicker access to life-changing treatments.”


This network is one of seven new Centres of Excellence established by Innovate UK to enhance the development and approval of medical innovations across the country.


More information online: ilmt.co/PL/NnpA 64081pr@reply-direct.com


Strategic appointment to drive biotech expansion


Nuclera, the innovative biotech company advancing protein expression


and optimisation with its cutting-edge eProtein


Discovery™ system, has appointed Seth Benson as Chief Financial Offi cer (CFO). Benson, joining CEO Dr Michael Chen and the executive team, will play a key role in propelling the company’s commercial growth following a successful USD $75 million fi nancing round.


Benson’s extensive fi nancial expertise, with over 20 years in the life sciences and healthcare sectors, will be crucial in advancing Nuclera’s strategic expansion. With a solid background in driving


strategic growth, optimising operations, and leading high-level fi nancial initiatives, Benson has a proven track record of scaling companies and navigating complex fi nancial landscapes. He has been instrumental in fundraising, acquisitions, restructurings, and IPOs, having previously contributed to Akoya Biosciences’ growth to over 300 employees and its eventual IPO.


Before joining Nuclera, Benson served as CFO at Vizgen, where he oversaw the company’s fi nances and guided it through the acquisition of Ultivue, a leader in spatial proteomics. Additionally, he held senior roles at Invaio Sciences, managing multi-national fi nance teams during key product launches and fundraising rounds. His career also includes investment banking positions at Morgan Stanley and Bank of America Merrill Lynch. Benson holds an MBA from Northwestern University’s Kellogg School of Management and a BSc in Biology from Duke University.


Benson expressed his enthusiasm for joining Nuclera, saying: “I’m thrilled to join Nuclera at such a dynamic time. The eProtein Discovery system is poised to revolutionise protein production workfl ows, and I’m excited to work with the team to drive growth and expand our global impact.”


CEO Dr Michael Chen commented: “Seth’s wealth of experience in scaling high-growth life science companies will be invaluable as we accelerate our commercial efforts. We also extend our gratitude to Jiahao for his signifi cant contributions to Nuclera’s success since its founding in 2013.”


Seth Benson.


More information online: ilmt.co/PL/RGOG 64083pr@reply-direct.com


Stephen Durrant steps down after decades in science


Stephen Durrant is retiring after a successful career that has signifi cantly contributed to the scientifi c community.


He began his career in education at CCAT in Cambridge before transitioning into industry with LKB Biochrom. Over the years, Stephen established himself as a trusted professional, working with several leading scientifi c companies.


In 1993, Stephen founded Eco Scientifi c Ltd, where he was instrumental in supporting Kin-Tek’s European operations as their sales, service, and support manager. His commitment to providing high-quality permeation tube and standards products earned him widespread recognition.


As Stephen moves into retirement, MA Controls Ltd will assume responsibility for the sales, service, and support of these products, ensuring continued service for customers.


Stephen plans to focus on charitable work in the Stroud area and pursue personal projects in the next phase of his life.


More information online: ilmt.co/PL/NnqA 64107pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48